FDA Pooled Analysis: Survival Outcomes With First-line Chemo-IO vs IO Alone for Treatment of Advanced NSCLC With PD-L1 Expression 1% to 49%

Results of this retrospective exploratory analysis suggest that chemo-IO regimens may improve OS and PFS compared with IO alone in most patients with previously untreated advanced NSCLC and tumor PD-L1 expression 1% to 49%.